CVS Health published its second-quarter report on 5 August 2026. We are writing about it today, 6 August.
What was reported
| Quarter | Year ago | Change | |
|---|---|---|---|
| Revenue | $106.1bn | +7.3% | |
| Operating income | +97.5% | ||
| Adjusted operating income | +35.4% | ||
| GAAP EPS | $2.31 | $0.80 | - |
| Adjusted EPS | $2.58 | $1.81 | +43% |
And immediately, the caveat
97.5% is not a 97.5% improvement
Operating income jumped 97.5%. But the company explains it itself:
the jump reflects the rise in adjusted operating income and the absence of $833 million in legacy litigation charges recorded in the prior year.
Meaning the year-ago quarter was low for a one-off reason.
The number describing the real operational improvement is adjusted operating income: plus 35.4% - still excellent, but a third of the headline figure.
And that also explains the EPS: $2.31 against $0.80 looks like a tripling, but the adjusted figure - $2.58 against $1.81 - is plus 43%.
The guidance: three raises
And this is the strong part of the report.
| Prior | Updated | |
|---|---|---|
| GAAP EPS | $6.24-6.44 | $6.84-7.04 |
| Adjusted EPS | $7.30-7.50 | $7.90-8.10 |
| Operating cash flow | at least $9.5bn | at least $11.5bn |
A 60-cent raise on both earnings measures, and $2 billion on the cash flow outlook.
The company explains the raise reflects improvement in the Health Care Benefits segment and in Pharmacy & Consumer Wellness - while maintaining a cautious view for the remainder of the year in light of continued elevated medical utilisation.
The insurance segment
Health Care Benefits revenue: $37.538 billion against $36.258 billion a year ago.
And this is the segment that decided the quarter. The company notes the EPS improvement came primarily from improved adjusted operating income in this segment, reflecting continued execution on its margin recovery plan.
The ratio that matters in this industry is the MBR - the medical benefit ratio, meaning what share of collected premiums actually goes to paying medical claims. The lower it is, the more profitable the insurance.
And why the stock fell anyway
The stock fell 5.08% to $99.12 on the reporting day.
The company itself gives a hint in its phrasing: it raises guidance "while maintaining a cautious view for the remainder of the year in light of continued elevated" medical utilisation.
High medical utilisation means insured members are consuming more medical services than expected - exactly what erodes health insurer profitability. A company that raises guidance while in the same breath warning that utilisation remains elevated is signalling that the improvement is not to be taken for granted.
My Angle
A personal opinion of Ilan Abramov - not advice, not a recommendation
This is another case this week where the company did everything right and the stock fell - and I think this time the explanation is simpler.
What actually happened: adjusted operating income rose 35.4%, and the company raised three guidance measures at once, including $2 billion added to the cash flow outlook. That is a good report.
And what I refuse to quote without a note: the 97.5% jump in operating income. The year-ago quarter included $833 million of one-off litigation charges. Excluding those the improvement is about a third of the headline - exactly the same correction I made this week for AMD and Uber.
And what I think weighed on the stock is the sentence about medical utilisation. Health insurance is a business where guidance rests on estimating how often people will see a doctor. When a company writes that it is staying cautious because utilisation is elevated, it is saying it does not fully trust its own forecast - which is right managerially and unsettling for the investor.
